151 related articles for article (PubMed ID: 29703027)
1. Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts: A case report and literature review.
Li J; Liu Y; Wang Z; Hu X; Xu R; Qian L
Medicine (Baltimore); 2018 Apr; 97(17):e0531. PubMed ID: 29703027
[TBL] [Abstract][Full Text] [Related]
2. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.
Montes de Jesus FM; Kwee TC; Nijland M; Kahle XU; Huls G; Dierckx RAJO; van Meerten T; Gheysens O; Dierickx D; Vergote V; Noordzij W; Glaudemans AWJM
Crit Rev Oncol Hematol; 2018 Dec; 132():27-38. PubMed ID: 30447925
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound for monitoring different stages of post-transplant lymphoproliferative disorder in a transplanted kidney: A case report and review of the literature.
Du ZS; Xie XH; Hu JJ; Fang Y; Ye L
Medicine (Baltimore); 2024 Feb; 103(8):e36206. PubMed ID: 38394510
[TBL] [Abstract][Full Text] [Related]
4. Application of contrast-enhanced ultrasonography in the diagnosis of post-kidney transplant lymphoproliferative disorder in native kidney- a case report.
Zhang JC; Lan HX; Zhao HJ; Lei YY; Ma L; Xie XY; Lu MD; Wang W
BMC Cancer; 2019 Nov; 19(1):1135. PubMed ID: 31752767
[TBL] [Abstract][Full Text] [Related]
5. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
6. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
7. Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.
Haruki K; Shiba H; Shimada J; Okui N; Iida T; Yanaga K
Clin J Gastroenterol; 2017 Feb; 10(1):47-51. PubMed ID: 27796825
[TBL] [Abstract][Full Text] [Related]
8. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
9. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.
Mendizabal M; Marciano S; dos Santos Schraiber L; Zapata R; Quiros R; Zanotelli ML; Rivas MM; Kusminsky G; Humeres R; Alves de Mattos A; Gadano A; Silva MO
Clin Transplant; 2013; 27(4):E469-77. PubMed ID: 23758407
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience.
Wójciak M; Gozdowska J; Dęborska-Materkowska D; Perkowska-Ptasińska A; Kosieradzki M; Nazarewski S; Durlik M
Transplant Proc; 2018 Sep; 50(7):2154-2158. PubMed ID: 30177129
[TBL] [Abstract][Full Text] [Related]
13. Lymphoproliferative disorders after renal transplantation: role of medical imaging.
Claudon M; Kessler M; Champigneulle J; Lefevre F; Hestin D; Renoult E
Eur Radiol; 1998; 8(9):1686-93. PubMed ID: 9866789
[TBL] [Abstract][Full Text] [Related]
14. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.
Banks CA; Meier JD; Stallworth CR; White DR
Ann Otol Rhinol Laryngol; 2012 May; 121(5):291-5. PubMed ID: 22724273
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Sprangers B; Riella LV; Dierickx D
Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey.
Khedmat H; Taheri S
Ann Transplant; 2010; 15(3):80-6. PubMed ID: 20877272
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y; Sun LY; Zhu ZJ; Wei L; Qu W; Wang L; Yuan LL; Zeng ZG
Int J Clin Pract; 2021 Apr; 75(4):e13843. PubMed ID: 33222369
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R
Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216
[TBL] [Abstract][Full Text] [Related]
20. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
